What is the share price of Bal Pharma Ltd (BALPHARMA) today?
The share price of BALPHARMA as on 4th July 2025 is ₹103.48. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bal Pharma Ltd (BALPHARMA) share?
The past returns of Bal Pharma Ltd (BALPHARMA) share are- Past 1 week: 3.43%
- Past 1 month: 4.72%
- Past 3 months: -15.34%
- Past 6 months: -15.37%
- Past 1 year: -13.70%
- Past 3 years: 9.33%
- Past 5 years: 142.91%
What are the peers or stocks similar to Bal Pharma Ltd (BALPHARMA)?
The peers or stocks similar to Bal Pharma Ltd (BALPHARMA) include:What is the dividend yield % of Bal Pharma Ltd (BALPHARMA) share?
The current dividend yield of Bal Pharma Ltd (BALPHARMA) is 1.15.What is the market cap of Bal Pharma Ltd (BALPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bal Pharma Ltd (BALPHARMA) is ₹164.75 Cr as of 4th July 2025.What is the 52 week high and low of Bal Pharma Ltd (BALPHARMA) share?
The 52-week high of Bal Pharma Ltd (BALPHARMA) is ₹157.98 and the 52-week low is ₹78.06.What is the PE and PB ratio of Bal Pharma Ltd (BALPHARMA) stock?
The P/E (price-to-earnings) ratio of Bal Pharma Ltd (BALPHARMA) is 22.79. The P/B (price-to-book) ratio is 2.38.Which sector does Bal Pharma Ltd (BALPHARMA) belong to?
Bal Pharma Ltd (BALPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bal Pharma Ltd (BALPHARMA) shares?
You can directly buy Bal Pharma Ltd (BALPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bal Pharma Ltd
BALPHARMA Share Price
103.480.11% (-0.11)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BALPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BALPHARMA Performance & Key Metrics
BALPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 22.85 | 2.38 | 1.15% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.15 | 6.59 | 0.81% |
BALPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BALPHARMA Company Profile
Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.
SUNPHARMA
PE Ratio
36.80
36.80
1Y Return
7.60%
7.60%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.18
23.18
1Y Return
2.20%
2.20%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.65
59.65
1Y Return
17.34%
17.34%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
19.24
19.24
1Y Return
0.89%
0.89%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.26
22.26
1Y Return
11.97%
11.97%
Buy Reco %
44.44
44.44
BALPHARMA Forecast
BALPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BALPHARMA
BALPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
BALPHARMA Income Statement
BALPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 231.95 | 213.21 | 226.02 | 172.94 | 251.67 | 286.36 | 305.16 | 342.07 | 305.29 | 305.29 | ||||||||||
Raw Materials | 122.58 | 112.48 | 121.58 | 81.23 | 145.90 | 172.42 | 190.64 | 192.82 | 273.52 | 273.53 | ||||||||||
| Power & Fuel Cost | 6.01 | 6.07 | 6.38 | 4.76 | 4.98 | 5.89 | 7.73 | 8.73 | ||||||||||||
| Employee Cost | 45.37 | 52.16 | 50.28 | 50.44 | 41.88 | 47.25 | 55.30 | 60.38 | ||||||||||||
| Selling & Administrative Expenses | 36.48 | 26.09 | 25.77 | 18.51 | 16.24 | 23.28 | 26.88 | 31.57 | ||||||||||||
| Operating & Other expenses | 3.66 | -2.66 | 3.31 | 11.12 | 16.89 | 8.40 | -1.58 | 14.02 | ||||||||||||
EBITDA | 17.85 | 19.07 | 18.70 | 6.88 | 25.78 | 29.12 | 26.19 | 34.55 | 31.77 | 31.76 | ||||||||||
| Depreciation/Amortization | 6.49 | 6.77 | 6.15 | 7.68 | 9.52 | 9.04 | 9.13 | 10.07 | 9.77 | 9.78 | ||||||||||
| PBIT | 11.36 | 12.30 | 12.55 | -0.80 | 16.26 | 20.08 | 17.06 | 24.48 | 22.00 | 21.98 | ||||||||||
| Interest & Other Items | 8.49 | 9.41 | 12.74 | 12.73 | 12.16 | 10.91 | 12.31 | 15.44 | 16.85 | 16.85 | ||||||||||
| PBT | 2.87 | 2.89 | -0.19 | -13.53 | 4.10 | 9.17 | 4.75 | 9.04 | 5.15 | 5.13 | ||||||||||
| Taxes & Other Items | 1.12 | 0.09 | -3.99 | -1.31 | -0.64 | 3.57 | 2.18 | 1.66 | -2.08 | -2.08 | ||||||||||
| Net Income | 1.75 | 2.80 | 3.80 | -12.22 | 4.74 | 5.60 | 2.57 | 7.38 | 7.23 | 7.21 | ||||||||||
| EPS | 1.29 | 1.98 | 2.68 | -8.62 | 3.27 | 3.78 | 1.68 | 4.69 | 4.56 | 4.56 | ||||||||||
| DPS | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.20 | 1.20 | 1.20 | ||||||||||
| Payout ratio | 0.77 | 0.51 | 0.37 | 0.00 | 0.31 | 0.26 | 0.59 | 0.26 | 0.26 | 0.26 |
BALPHARMA Company Updates
BALPHARMA Stock Peers
BALPHARMA Past Performance & Peer Comparison
BALPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bal Pharma Ltd | 22.79 | 2.38 | 1.15% |
| Sun Pharmaceutical Industries Ltd | 36.80 | 5.99 | 0.95% |
| Cipla Ltd | 23.18 | 3.91 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.65 | 16.63 | 0.95% |
BALPHARMA Stock Price Comparison
Compare BALPHARMA with any stock or ETFCompare BALPHARMA with any stock or ETF
BALPHARMA
BALPHARMA Holdings
BALPHARMA Shareholdings
BALPHARMA Promoter Holdings Trend
BALPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BALPHARMA Institutional Holdings Trend
BALPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BALPHARMA Shareholding Pattern
BALPHARMA Shareholding Pattern
BALPHARMA Shareholding History
BALPHARMA Shareholding History
Foreign Institutions
smallcases containing BALPHARMA stock
smallcases containing BALPHARMA stock
Looks like this stock is not in any smallcase yet.
BALPHARMA Events
BALPHARMA Events
BALPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BALPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.51 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BALPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BALPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.51 every year
BALPHARMA Upcoming Dividends
BALPHARMA Upcoming Dividends
No upcoming dividends are available
BALPHARMA Past Dividends
BALPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹1.20
Dividend/Share
₹1.20
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 13, 2022
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 13, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 17, 2019
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 17, 2019
BALPHARMA Stock News & Opinions
BALPHARMA Stock News & Opinions
Articles & Videos
Corporate
Board of Bal Pharma recommends final dividend
Bal Pharma announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 1.2 per equity Share (i.e. 12%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bal Pharma consolidated net profit declines 0.73% in the March 2025 quarter
Net profit of Bal Pharma declined 0.73% to Rs 5.43 crore in the quarter ended March 2025 as against Rs 5.47 crore during the previous quarter ended March 2024. Sales declined 13.47% to Rs 81.88 crore in the quarter ended March 2025 as against Rs 94.63 crore during the previous quarter ended March 2024. For the full year,net profit declined 2.30% to Rs 7.22 crore in the year ended March 2025 as against Rs 7.39 crore during the previous year ended March 2024. Sales declined 10.65% to Rs 303.08 crore in the year ended March 2025 as against Rs 339.22 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales81.8894.63 -13 303.08339.22 -11 OPM %9.3310.14 -9.759.06 - PBDT4.777.91 -40 14.9119.12 -22 PBT2.595.75 -55 5.149.05 -43 NP5.435.47 -1 7.227.39 -2 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bal Pharma to declare Quarterly Results
Bal Pharma will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Bal Pharma Ltd leads gainers in 'B' group
Chemcrux Enterprises Ltd, Maral Overseas Ltd, Growington Ventures India Ltd and Orchasp Ltd are among the other gainers in the BSE's 'B' group today, 03 April 2025.Bal Pharma Ltd soared 20.00% to Rs 109.04 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 1.98 lakh shares were traded on the counter so far as against the average daily volumes of 5629 shares in the past one month. Chemcrux Enterprises Ltd surged 19.99% to Rs 143.15. The stock was the second biggest gainer in 'B' group. On the BSE, 36065 shares were traded on the counter so far as against the average daily volumes of 13458 shares in the past one month. Maral Overseas Ltd spiked 19.99% to Rs 75.34. The stock was the third biggest gainer in 'B' group. On the BSE, 21729 shares were traded on the counter so far as against the average daily volumes of 1866 shares in the past one month. Growington Ventures India Ltd jumped 19.71% to Rs 3.28. The stock was the fourth biggest gainer in 'B' group. On the BSE, 12.2 lakh shares were traded on the counter so far as against the average daily volumes of 4.94 lakh shares in the past one month. Orchasp Ltd exploded 15.41% to Rs 3.67. The stock was the fifth biggest gainer in 'B' group. On the BSE, 12.39 lakh shares were traded on the counter so far as against the average daily volumes of 2.02 lakh shares in the past one month. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Bal Pharma consolidated net profit declines 46.07% in the December 2024 quarter
Net profit of Bal Pharma declined 46.07% to Rs 0.48 crore in the quarter ended December 2024 as against Rs 0.89 crore during the previous quarter ended December 2023. Sales declined 10.42% to Rs 73.15 crore in the quarter ended December 2024 as against Rs 81.66 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales73.1581.66 -10 OPM %10.599.54 - PBDT3.254.23 -23 PBT0.571.27 -55 NP0.480.89 -46 Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Bal Pharma standalone net profit declines 7.94% in the December 2024 quarter
Net profit of Bal Pharma declined 7.94% to Rs 1.16 crore in the quarter ended December 2024 as against Rs 1.26 crore during the previous quarter ended December 2023. Sales declined 10.55% to Rs 72.89 crore in the quarter ended December 2024 as against Rs 81.49 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales72.8981.49 -11 OPM %10.599.61 - PBDT3.534.23 -17 PBT1.201.68 -29 NP1.161.26 -8 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Bal Pharma to hold board meeting
Bal Pharma will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Bal Pharma consolidated net profit rises 9.47% in the September 2024 quarter
Net profit of Bal Pharma rose 9.47% to Rs 1.04 crore in the quarter ended September 2024 as against Rs 0.95 crore during the previous quarter ended September 2023. Sales declined 20.37% to Rs 73.69 crore in the quarter ended September 2024 as against Rs 92.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales73.6992.54 -20 OPM %10.448.32 - PBDT3.844.02 -4 PBT1.361.60 -15 NP1.040.95 9 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Bal Pharma schedules board meeting
Bal Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Bal Pharma to convene board meeting
Bal Pharma will hold a meeting of the Board of Directors of the Company on 9 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.04%, vs industry avg of 10.14%
Over the last 5 years, market share stayed at 0.07%